This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sequenom's CEO Discusses Q1 2012 Results - Earnings Call Transcript

Sequenom (SQNM)

Q1 2012 Earnings Call

May 3, 2012, 5:00 p.m. ET


Marcy Graham - Senior Director, IR

Harry Hixson - Chairman and CEO

Paul Maier – CFO

Ron Lindsay - Director and EVP

Bill Welch - SVP, Diagnostics

Dirk van den Boom - SVP, R&D


David Ferreiro – Oppenheimer & Co.

Brian Weinstein - William Blair

Nandita Koshal - Barclays Capital

William Quirk – Piper Jaffray

Kevin DeGeeter - Ladenburg Thalmann & Co.

Elemer Piros - Rodman & Rodman & Renshaw

Jon Wood (Brandon)– Jefferies & Co.

Zarak Khurshid - Wedbush Securities



Good afternoon, and welcome to the Sequenom Inc. first quarter 2012 earnings conference call. (Operator Instructions).

I would now like to turn this conference over to Marcy Graham, Senior Director of Investor Relations. Please go ahead.

Marcy Graham

Thank you, Laura. Welcome to the Sequenom conference call to discuss operating results for the first quarter of 2012. Joining me today are Dr. Harry Hixson, Chairman and CEO, Paul Maier, CFO, Dr. Ron Lindsay, Director and Executive Vice President of Research and Development, Bill Welch, Senior Vice President of Diagnostics and Dr. Dirk van den Boom, Senior Vice President of Research and Development, who will join us later for the Q&A portion of our call.

This call is also being broadcast live over the web and will be available for replay through Friday, May 11 th, 2012, on the investor section of our website at Before we begin, please note that this call will include a discussion of Sequenom and Sequenom CMM’s current plans and intentions regarding product development, operations, commercialization, including diagnostic test projections, goals and other matters, as well as expectations regarding Sequenom’s future financial performance and reporting, statements that are not historical facts, but are forward-looking statements. Forward-looking statements are not guarantees of performance, they involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For information about the risks and uncertainties that Sequenom faces, please refer to the risk factors set forth in our recent filings with the Securities and Exchange Commission. Sequenom assumes no obligation and expressly disclaims any duty to update any forward-looking statements to reflect events or circumstances after today’s call, or to reflect the occurrence of unanticipated events. With that, I would like to now turn the call over to Dr. Harry Hixson. Harry?

Harry Hixson

Thank you, Marcy. Good afternoon and thanks for joining us on today’s call to discuss Sequenom’s first quarter for 2012. We are pleased to report that Sequenom and the Sequenom Center for Molecular Medicine, or Sequenom CMM, enjoyed a very productive start to 2012. During this first full quarter since the launch of the MaterniT21 PLUS laboratory developed test, or LDT, unit test volumes for diagnostic testing services grew at a rate faster than our internal goals, while we work to expand our operational capabilities, to manage this growth going forward.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%
YHOO $36.60 0.03%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs